Review article · 2021
CommentaryPublished 29 Oct 2024
Chimeric Antigen Receptor T-Cell Therapy
Department of Oncology, Columbia University College of Physicians and Surgeons, United States
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chimeric Antigen Receptor (CAR) T-cell therapy represents a paradigm shift in cancer immunotherapy, offering a highly targeted approach for treating hematological malignancies and solid tumors. This therapy involves genetically engineering a patient’s T-cells to express specific CARs, enabling them to recognize and eliminate tumor cells with remarkable precision. Despite its groundbreaking efficacy, challenges such as cytokine release syndrome, neurotoxicity, and resistance mechanisms remain critical hurdles. This article explores the principles, clinical advancements, therapeutic outcomes, and limitations of CAR T-cell therapy, providing insights into ongoing research aimed at enhancing its efficacy and expanding its application to diverse malignancies. Key future directions include improving CAR T-cell persistence, targeting tumor heterogeneity, and overcoming the immunosuppressive tumor microenvironment.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 11 Dec 2023
The Intricacies of Oncological Immunotherapy and Chimeric Antigen Receptor T-Cell Therapy
Short communication · 2020
Prospects for Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Glioblastoma Multiforme: A Review of the Literature
Research article · 29 Jul 2019
Tumor and Cancer Immunology 2017: Chimeric antigen receptor modified T-cell redirected to EGFR in patients with metastatic and advanced pancreatic adenocarcinoma and biliary tract cancers - Weidong Han- PLA General Hospital
Conference abstract · 28 Jul 2016
Phase I/IIa trial of chimeric antigen receptor modified T cells against CD133 in patients with sorafenib refractory hepatocellular carcinoma (HCC) and other solid tumors
More from this journal
The newest in Insights in Gynecologic Oncology.
Research article · 29 Dec 2025
Evolving Biomarkers for Ovarian Cancer Prognostication
Rapid communication · 29 Dec 2025
Gynecologic Cancer Screening: Advancements for Early Detection
Rapid communication · 29 Dec 2025
PI3K Pathway: Targeting Ovarian Cancer Therapeutics
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInsights in Gynecologic Oncology
- SubjectOncology & Cancer
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Deepali Jain”
